CA2558708A1 - Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer - Google Patents

Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer Download PDF

Info

Publication number
CA2558708A1
CA2558708A1 CA002558708A CA2558708A CA2558708A1 CA 2558708 A1 CA2558708 A1 CA 2558708A1 CA 002558708 A CA002558708 A CA 002558708A CA 2558708 A CA2558708 A CA 2558708A CA 2558708 A1 CA2558708 A1 CA 2558708A1
Authority
CA
Canada
Prior art keywords
disease
treatment
alzheimer
dementia
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002558708A
Other languages
English (en)
Inventor
Lars Lykke Thomsen
Anders Gersel Pedersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H. Lundbeck A/S
Lars Lykke Thomsen
Anders Gersel Pedersen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S, Lars Lykke Thomsen, Anders Gersel Pedersen filed Critical H. Lundbeck A/S
Priority claimed from CA002426492A external-priority patent/CA2426492C/fr
Publication of CA2558708A1 publication Critical patent/CA2558708A1/fr
Abandoned legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002558708A 2002-05-31 2003-05-08 Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer Abandoned CA2558708A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200200844 2002-05-31
DKPA200200844 2002-05-31
CA002426492A CA2426492C (fr) 2002-05-31 2003-05-08 Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002426492A Division CA2426492C (fr) 2002-05-31 2003-05-08 Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
CA2558708A1 true CA2558708A1 (fr) 2003-09-16

Family

ID=37451510

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002558708A Abandoned CA2558708A1 (fr) 2002-05-31 2003-05-08 Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer

Country Status (1)

Country Link
CA (1) CA2558708A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048871A1 (fr) * 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Mémantine pour l'amélioration de la performance cognitive chez des sujets

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048871A1 (fr) * 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Mémantine pour l'amélioration de la performance cognitive chez des sujets

Similar Documents

Publication Publication Date Title
EP1509232B1 (fr) Combinaison d'un antagoniste de n-methyl d-aspartate et d'inhibiteurs de l'esterase d'acetylcholine pour le traitement de la maladie d'alzheimer
AU2019203832B2 (en) Fenfluramine for use in the treatment of dravet syndrome
CZ187097A3 (cs) Farmaceutický prostředek
EA015566B1 (ru) Применение пептидного соединения для добавочной терапии к антагонисту дофамина и фармацевтическая композиция, его содержащая
WO2021262196A1 (fr) Compositions et méthodes de traitement de la maladie d'alzheimer et de la maladie de parkinson
WO2015089111A1 (fr) Nouveaux procédés
ZA200507439B (en) Use of carbamazepine derivatives for the treatment of agitation in dementia patients
US4481206A (en) Spiro succinimide derivative in the treatment of dementia of the Alzheimer type
US7884096B2 (en) Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2426492C (fr) Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer
NZ236055A (en) Use of pyrimidine-substituted piperazine derivative in the treatment of depression
CA2558708A1 (fr) Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer
US4017614A (en) Compositions for the relief of migraine
JP2593910B2 (ja) パニック障害の予防又は抑制剤
JP2003523385A (ja) 神経変性疾患の治療法
NZ249041A (en) Use of brofaromine(4-(7-bromo-5-methoxy-2-benzofuranyl)-piperdine) for treating post-traumatic stress disorder
KR20220020832A (ko) 단백질 감염에 사용하기 위한 3원 약학 조성물
WO2005097138A2 (fr) Combinaisons comprenant de l'oxcarbazepine pour le traitement de troubles affectifs
David Oxcarbazepine, Top&mate, Zonisamide, and Levetiracetam: Potential Use in Neuropathic Pain
JPS58174317A (ja) ジベンゾシクロヘプタジエンとコデルゴクリンを含有する薬学的組成物
MXPA03008839A (es) Formulacion de tabletas de lamotrigina de liberacion sostenida.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead